| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
35,544 |
30,748 |
$1.82M |
| 96521 |
|
1,656 |
469 |
$184K |
| 99441 |
|
5,880 |
4,218 |
$120K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,631 |
469 |
$91K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
1,615 |
467 |
$55K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
663 |
611 |
$27K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
216 |
213 |
$17K |
| 99493 |
|
137 |
122 |
$12K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
289 |
271 |
$8K |
| J1817 |
Insulin for administration through dme (i.e., insulin pump) per 50 units |
941 |
285 |
$7K |
| 99492 |
|
41 |
41 |
$4K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
67 |
67 |
$4K |
| J1955 |
Injection, levocarnitine, per 1 gm |
165 |
53 |
$3K |
| 86328 |
|
40 |
34 |
$1K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
196 |
186 |
$103.71 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
25 |
14 |
$83.29 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
113 |
81 |
$32.83 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
1,545 |
1,321 |
$0.02 |
| G9622 |
Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method |
1,539 |
1,307 |
$0.00 |
| G9584 |
Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy |
1,560 |
1,328 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
1,547 |
1,327 |
$0.00 |
| G8539 |
Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies is documented within two days of the functional outcome assessment |
1,605 |
1,352 |
$0.00 |
| 1124F |
|
909 |
783 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
565 |
482 |
$0.00 |
| 4004F |
|
95 |
83 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
212 |
187 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
759 |
657 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
467 |
395 |
$0.00 |
| 1036F |
|
906 |
775 |
$0.00 |
| 1123F |
|
129 |
109 |
$0.00 |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
37 |
37 |
$0.00 |